PAINREFORM LTD (PRFX) Stock News

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

TEL AVIV, Israel, Dec. 27, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (

Dow Surges 100 Points, Carnival Earnings Top Views

Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

“Power Nickel (TSX.V: PNPN) (OTCQB: PNPNF) Announces Dividend – MIGI, PRFX, PBM, CSDX Stocks Trending Now!”

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

TEL AVIV, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

This notification has no immediate effect on the listing or trading of PainReform’s ordinary shares on the Nasdaq Capital Market TEL AVIV, Israel, Nov. ...

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Positive Compatibility Results Reinforce Safety and Efficacy of PRF-110 in Post-Surgical Pain Management...

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

TEL AVIV, Israel, Sept. 10, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (

PainReform Bunionectomy Study Observations Confirm Optimal Delivery Method for PRF-110 in Bunionectomy Procedures

PRF-110 Demonstrates Superior Coverage and Stability in Surgical Wounds Findings Highlight PRF-110’s Competitive Edge Over Leading Pain Management...

PRFX Stock Earnings: PainReform Beats EPS for Q2 2024

PRFX stock results show that PainReform beat analyst estimates for earnings per share the second quarter of 2024.

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

TEL AVIV, Israel, Aug. 20, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (

PainReform Provides Business Update for the Second Quarter of 2024

Reaches full enrollment in the second part of Phase 3 clinical trial of PRF-110 in bunionectomy Remains on track to announce top-line data in late...

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

TEL AVIV, Israel, Aug. 07, 2024 (GLOBE NEWSWIRE) --  PainReform Ltd. (Nasdaq: PRFX) (

PainReform Ltd. Announces Favorable Wound Healing Data in Human Clinical Trials for PRF-110

PRF-110 promoted normal wound healing and prevented scar formation following surgical procedures Company reaffirms it is on track to report top-line...

PainReform’s New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

New process expected to significantly bolster future commercialization efforts...

PainReform Files Patent Covering Highly Scalable Manufacturing Process for PRF-110 Following Successful Completion and Testing

TEL AVIV, Israel, July 24, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (

PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110

Top line data to be reported in the second half of 2024...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

Pre-market stock movers are worth checking out on Friday as we dive into all of the biggest news moving shares this morning!

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday

Pre-market stock movers are worth checking out on Thursday as we break down all of the hottest stock market news this morning!

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel, May 31, 2024 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (